Tourmaline Bio Stock Price, News & Analysis

Tourmaline Bio (NASDAQ: TRML) announced it will host a conference call and webcast on May 20, 2025 at 8:30 a.m. ET to present topline results from its Phase 2 TRANQUILITY trial of pacibekitug. The study evaluates the drug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. The presentation will feature management alongside Dr. Deepak L. Bhatt, Director of Mount Sinai Fuster Heart Hospital and Chair of Tourmaline's Cardiovascular Scientific Advisory Board.

Tourmaline Bio (NASDAQ: TRML) reported Q1 2025 financial results and business updates. The company's Phase 2 TRANQUILITY trial for pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease is over-enrolled with 143 participants and remains on track for topline data in Q2 2025. The company ended Q1 with $275.3 million in cash, providing runway into H2 2027. Financial results showed R&D expenses of $20.3 million (up from $11.4M in Q1 2024) and a net loss of $23.0 million ($0.89 per share). The company is advancing pacibekitug for potential treatment of atherosclerotic cardiovascular disease (ASCVD) and abdominal aortic aneurysm (AAA), with plans to share additional development details alongside TRANQUILITY data. Their Phase 2b spiriTED trial for Thyroid Eye Disease continues with topline data expected in H2 2025.

Tourmaline Bio (NASDAQ: TRML) has reported its Q4 and full year 2024 financial results. The company has successfully over-enrolled its Phase 2 TRANQUILITY trial to 143 participants, with topline data expected in Q2 2025. The trial evaluates pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease.

Financial highlights include a strong cash position of $294.9 million as of December 31, 2024, providing runway into H2 2027. R&D expenses increased to $67.0 million for FY2024, up from $32.4 million in 2023. Net loss widened to $73.2 million for FY2024 compared to $42.1 million in 2023.

The company strengthened its Cardiovascular Scientific Advisory Board with the appointments of several distinguished experts and continues to advance its clinical programs in cardiovascular inflammation and thyroid eye disease, with the Phase 2b spiriTED trial results expected in H2 2025.

Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, has announced its participation in the upcoming Leerink's Global Healthcare Conference 2025.

The company's Co-Founder and CEO, Sandeep Kulkarni, MD, will engage in a fireside chat scheduled for Tuesday, March 11, 2025, at 4:20 pm ET in Miami. Interested parties can access both the live webcast and replay through the 'Events and Presentations' section under News & Investors on Tourmaline Bio's website at ir.tourmalinebio.com.

Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York.

The company's Co-Founder and CEO, Sandeep Kulkarni, MD, will participate in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:30 pm ET. Investors and interested parties can access both the live webcast and replay of the presentation through the 'Events and Presentations' section on Tourmaline Bio's investor relations website at ir.tourmalinebio.com.

Tourmaline Bio (NASDAQ: TRML) has appointed Dr. Paul M. Ridker to its Cardiovascular Scientific Advisory Board. Dr. Ridker, who serves as Eugene Braunwald Professor of Medicine at Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, brings over 30 years of expertise in cardiovascular disease research.

Dr. Ridker's contributions include developing the first FDA-approved diagnostic test for vascular inflammation (hs-CRP), demonstrating statin therapy's dual lipid-lowering and anti-inflammatory effects, and proving the inflammation hypothesis of atherothrombosis in humans. His work has led to the development of various anti-inflammatory agents targeting heart disease.

This appointment comes as Tourmaline awaits results from its Phase 2 TRANQUILITY trial and prepares for the future development of pacibekitug to reduce inflammation in cardiovascular diseases.

Tourmaline Bio (NASDAQ: TRML) announced key updates at its Investor Day, highlighting progress in its cardiovascular inflammation programs. The company's Phase 2 TRANQUILITY trial has exceeded its enrollment target with 143 patients, surpassing the original 120-patient goal. Topline data is expected in Q2 2025.

The company expanded its Cardiovascular Scientific Advisory Board with two new appointments: Dr. Deepak L. Bhatt as Chair and Dr. Dipender Gill. Additionally, Tourmaline nominated abdominal aortic aneurysm (AAA) as a second cardiovascular indication for its drug pacibekitug, with plans for a Phase 2 proof-of-concept trial after TRANQUILITY results.

Regarding its Thyroid Eye Disease program, the initiation of Phase 3 trials will depend on results from the ongoing Phase 2b spiriTED trial, with topline data expected in H2 2025.

Tourmaline Bio (NASDAQ: TRML) has announced its upcoming virtual Investor Day scheduled for December 10, 2024, at 10 a.m. ET. The event will feature presentations from the company's leadership team and special guest Dr. Marc Bonaca, a distinguished cardiologist and Executive Director of CPC Clinical Research. Dr. Bonaca, who serves on Tourmaline's Cardiovascular Scientific Advisory Board, will join discussions about the company's development plans for pacibekitug, their therapeutic candidate aimed at addressing unmet needs in immune and inflammatory diseases.

Tourmaline Bio reported Q3 2024 financial results with a net loss of $20.2 million ($0.78 per share), compared to $5.6 million in Q3 2023. The company maintains a strong cash position of $314.4 million, providing runway into 2027. Research and development expenses increased to $19.3 million from $3.8 million year-over-year, while general and administrative expenses rose to $5.1 million from $2.9 million.

The company remains on track to report topline data from its Phase 2 TRANQUILITY trial in first half of 2025 and formed a Cardiovascular Scientific Advisory Board in October 2024. Additionally, Tourmaline expects topline data from the pivotal spiriTED Phase 2b trial in TED in second half of 2025.